

b.) Remarks

To reduce the issues, claims 23, 71, 73, 75, 77 and 79 have been amended to utilize a “consisting essentially of” transition. As understood by those of ordinary skill in the art, when (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine is administered, it is accompanied by inactive pharmaceutically acceptable carriers, diluents, coatings and the like. Such are intended to be encompassed by the pending claims.

Additionally, claims 25, 72, 74, 76, 78 and 80 are cancelled as superfluous. Accordingly, no new matter has been added.

The relevant prior art of record, Greenlee, teaches use of adenosine A<sub>2A</sub> receptor antagonists in combination with antidepressants or anxiolytic agents in treating anxiety-related disorders. The above-amended claims now exclude such antidepressants and anxiolytic agents.

Entry hereof is earnestly solicited.

Applicants’ undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,

/Lawrence S. Perry/  
Lawrence S. Perry  
Attorney for Applicants  
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO  
1290 Avenue of the Americas  
New York, New York 10104-3800  
Facsimile: (212) 218-2200  
LSP\ac